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ABSTRACT 
  This study tested the anti-diabetic and hypoglycemic effect of the 
Cinnamon which is available in Sudan. Cinnamon is use in so many 
countries for treatment of bacterial and fungal disease, cold influenza and 
as antioxidant agent. Recently people discovered that Cinnamum cassia 
induced hypoglycemia in patient with type2 diabetes mellitus. C.cassia is 
closely like C. verum (the species found in Sudanese markets). This study 
was carried out in Wister albino rats. 
  In experiment (1), the rats were divided into three groups A, B 
and C; each group consisted of   six rats. The serum glucose level of all 
rats (A, B and C) was measured at 0h after 18 hour fasting then they were 
injected with glucose solution 50% concentration to induce hyperglycemia. 
Group B after glucose load was treated orally with Glibenclamide as 
standard drug. Group C which was also hyperglycemic rats was treated 
orally with     C. verum (1g/kgBwt), then the plasma glucose level was 
measured after 1, 2 and 4h.  
 In experiment (2): Normoglycemic fasting rats were divided into 
two groups D and E, each group consisted of six rats. After 18 hours 
fasting glucose level of both group (D and E) was measured at 0h. Then 
the rats of group D received orally C. verum in dose of 1g/kgBwt while 
rats of group E were untreated control group. Then serum glucose level of 
both groups was measured at hour 1, 2 and 4.  
         Experiment 1 showed that Glibenclamide lowered significantly 
serum glucose level at hour 1, 2 and 4 when compared to control group 
xi 
 
while C. verum lowered significantly serum glucose level at hour 2 and 
nonsignificantly at hour 4. 
 Experiment (2) showed administration of C. verum to 
normoglycemic rats lowered significantly serum glucose level at hour 4 
(P≤ 0.01) and nonsignificantly at hour 1 and 2.  
  This experiment showed that Cinnamum sp which found in all 
market in Sudan has antidiabetic and hypoglycemic effect in 
hyperglycemic rats. Also the same dose has hypoglycemic effect in 
normoglycemic rats.   
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  ﻤﻠﺨﺹ ﺍﻻﻁﺭﻭﺤﻪ
ﺍﻟﺨﺎﻓﺽ ﻟﺘﺭﻜﻴﺯ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻲ ﺍﻟﺩﻡ ﻭﺍﻷﺜﺭ ﺍﻟﻤﻌﺎﻟﺞ ﻟﻤـﺭﺽ  ﺍﻷﺜﺭ         ﻓﻲ ﻫﺫﻩ ﺍﻻﻁﺭﻭﺤﻪ ﺘﻡ ﺩﺭﺍﺴﺔ   
ﻭﻨﺒﺎﺕ ﺍﻟﻘﺭﻓﺔ ﻴﺴﺘﺨﺩﻡ ﻓﻲ ﻋﺩﺩ ﻜﺜﻴﺭ ﻤﻥ ﺩﻭل . ﺍﻟﺴﻜﺭﻯ ﺒﻭﺍﺴﻁﺔ ﻨﺒﺎﺕ ﺍﻟﻘﺭﻓﺔ ﺍﻟﻨﻭﻉ ﺍﻟﻤﺘﻭﻓﺭ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ 
 ﺍﻟﺒﻜﺘﻴﺭﻴﻪ ﻭﺍﻟﻔﻁﺭﻴـﻪ ﻜﻤـﺎ ﻴﻌـﺎﻟﺞ ﺍﻹﺼﺎﺒﺎﺕﺴﻁﺔ  ﺍﻟﺠﻬﺎﺯ ﺍﻟﻬﻀﻤﻲ ﺒﻭﺍ ﺃﻤﺭﺍﺽﺍﻟﻌﺎﻟﻡ ﻟﻌﻼﺝ ﻜﺜﻴﺭ ﻤﻥ 
 ﻓﺎﻋﻠﻴﺘﻪ ﻜﻌﻼﺝ ﻟﻤﺭﺽ ﺍﻟـﺴﻜﺭﻯ ﻤـﻥ ﺃﺜﺒﺘﺕ ﻭﺃﺨﻴﺭﺍﹰ. ﻨﺯﻻﺕ ﺍﻟﺒﺭﺩ ﻭﻗﺩ ﺍﺜﺒﺕ ﻓﻌﺎﻟﻴﺘﻪ ﻜﻤﻀﺎﺩ ﻟﻼﻜﺴﺩﺓ 
ﻪ ﺒـﺎﻟﻨﻭﻉ ﻓﻲ ﻋﻼﺝ ﻤﺭﺽ ﺍﻟﺴﻜﺭﻯ ﻫﻭ ﻜﺜﻴﺭ ﺍﻟﺸﺒ ﻭﺍﻟﻨﻭﻉ ﺍﻟﺫﻱ ﺍﺜﺒﺕ ﻓﻌﺎﻟﻴﺘﻪ . ﺍﻹﻨﺴﺎﻥﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻓﻲ 
  .ﺍﻥ ﻭﺴﺘﺭ ﺍﻟﺒﻴﻀﺎﺀﺫ ﻤﻥ ﺠﺭﻭﺍﻹﻨﺎﺙﻫﺫﺍ ﺍﻟﺒﺤﺙ ﻋﻠﻲ ﺍﻟﺫﻜﻭﺭ  ﺍﻟﺘﺠﺎﺭﺏ ﻓﻲ ﺃﺠﺭﻴﺕ. ﺍﻟﻤﺘﻭﻓﺭ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ
 ﺤﻘﻨﻬـﺎ ﻭﺍﻟﺘﻲ ﺘﻡ ( ﺃ ﻭ ﺏ ﻭ ﺱ ) ﺜﻼﺜﺔ ﻤﺠﻤﻭﻋﺎﺕ ﺇﻟﻲﺍﻥ ﺫ ﺘﻡ ﺘﻘﺴﻴﻡ ﺍﻟﺠﺭ ﺍﻷﻭﻟﻲﻓﻲ ﺍﻟﺘﺠﺭﺒﺔ             
ﻜﻴﻠﻭﺠﺭﺍﻡ ﻤﻥ ﻭﺯﻥ ﺍﻟﺤﻴﻭﺍﻥ ﻟﺭﻓﻊ ﺘﺭﻜﻴﺯ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻲ /ﺠﺭﺍﻡ2ﺠﺭﻋﺔ  ﺒ %(05 ﺘﺭﻜﻴﺯﺒ)  ﺍﻟﺠﻠﻜﻭﺯ ﺒﻤﺤﻠﻭل
 ﺴﺎﻋﺔ ﺜﻡ ﺍﺨﺫ 81 ﺍﻟﻔﺌﺭﺍﻥ ﻟﻠﺼﻴﺎﻡ ﻟﻤﺩﺓ ﺇﺨﻀﺎﻉﺒﺎﺭ ﺘﺤﻤل ﺍﻟﺠﻠﻜﻭﺯ ﻭﻫﻭ ﺒﻌﺩ  ﺍﺨﺘ ﺇﺠﺭﺍﺀ ﺃﺜﻨﺎﺀﻭﺫﻟﻙ . ﺍﻟﺩﻡ
 ﺴﺎﻋﺎﺕ ﻟﻘﻴﺎﺱ ﻭﺃﺭﺒﻊ ﻭﺴﺎﻋﺘﻴﻥ ﺔﻋﻴﻨﺎﺕ ﻤﻥ ﺩﻤﻬﺎ ﻗﺒل ﺤﻘﻥ ﺍﻟﺠﻠﻜﻭﺯ ﻤﺒﺎﺸﺭﺓ ﺜﻡ ﺒﻌﺩ ﺤﻘﻥ ﺍﻟﺠﻠﻜﻭﺯ ﺒﺴﺎﻋ 
ﺒﻌـﺩ ( ﺏ)ﺍﻟﻤﺠﻤﻭﻋـﺔ . ﺍﺴﺘﻌﻤﻠﺕ ﻜﻤﺠﻤﻭﻋﺔ ﻀﺒﻁ ﻭﻤﻘﺎﺭﻨـﺔ ( ﺃ)ﺍﻟﻤﺠﻤﻭﻋﺔ . ﺘﺭﻜﻴﺯ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻲ ﺍﻟﺩﻡ 
 ﻟﻠﻤﻌﺎﻟﺠﺔ ﺒﻭﺍﺴﻁﺔ ﺩﻭﺍﺀ ﻤﺠﺭﺏ ﻓﻲ ﻋﻼﺝ ﺩﺍﺀ ﺍﻟـﺴﻜﺭﻱ ﻭﻫـﻭ ﺃﺨﻀﻌﺕﻠﻜﻭﺯ ﺍﺴﺘﺤﺩﺍﺙ ﺤﺎﻟﺔ ﺭﻓﻊ ﺍﻟﺠ 
 ﺠﺭﻋـﺔ ﻤـﻥ ﺃﺨﺫﺕﻭﺍﻟﺘﻲ ﺍﺴﺘﺤﺩﺙ ﻓﻴﻬﺎ ﺤﺎﻟﺔ ﺭﻓﻊ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻲ ﺍﻟﺩﻡ ﺜﻡ ( ﺱ)ﺍﻟﻤﺠﻤﻭﻋﺔ . ﺍﻟﻘﻠﻴﺒﻨﻜﻼﻤﻴﺩ
  . ﻜﻴﻠﻭﺠﺭﺍﻡ ﻤﻥ  ﻭﺯﻥ ﺍﻟﺤﻴﻭﺍﻥ/ﺠﺭﺍﻡ1ﺍﻟﻘﺭﻓﺔ ﺒﻤﻘﺩﺍﺭ  
 81 ﻟﻠﺼﻴﺎﻡ ﻟﻤﺩﺓ ﺇﺨﻀﺎﻋﻬﺎﺒﻌﺩ ( ﻯ) ﻭ (ﺩ) ﻤﺠﻤﻭﻋﺘﺒﻥ ﺇﻟﻰﺍﻥ ﺫ        ﻓﻲ ﺍﻟﺘﺠﺭﺒﺔ ﺍﻟﺜﺎﻨﻴﺔ ﺘﻡ ﺘﻘﺴﻴﻡ ﺍﻟﺠﺭ   
ﻭﺍﻟﺘﻲ ﻟﻡ ﺘﺨﻀﻊ ( ﺩ)ﺍﻟﻤﺠﻤﻭﻋﺔ . ﻜﻴﻠﻭﺠﺭﺍﻡ ﻤﻥ ﻭﺯﻥ ﺍﻟﺤﻴﻭﺍﻥ  1/ ﺠﺭﺍﻡ 1 ﺍﻟﻘﺭﻓﺔ ﺒﺎﻟﺠﺭﻋﺔ ﺃﻋﻁﻴﺕﺴﺎﻋﺔ 
  .ﻀﺒﻁ ﻭ ﻤﻘﺎﺭﻨﺔ  ﻤﻌﺎﻟﺠﺎﺕ ﺍﺴﺘﻌﻤﻠﺕ ﻜﻤﺠﻤﻭﻋﺔﻷﻱ
 ﺩﻭﺍﺀ ﺍﻟﻘﻠﻴﺒﻨﻜﻼﻤﻴﺩ ﻴﺨﻔﺽ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻲ ﺍﻟﺩﻡ ﻤﻌﻨﻭﻴـﺎ ﻓـﻲ ﺍﻟـﺴﺎﻋﺔ ﺃﻥ ﺃﻅﻬﺭﺕ ﺍﻷﻭﻟﻲ        ﺍﻟﺘﺠﺭﺒﺔ   
 ﻭﺍﻟﺜﺎﻨﻴﺔ ﻭﺍﻟﺭﺍﺒﻌﺔ ﻋﻨﺩ ﻤﻘﺎﺭﻨﺘﻪ ﺒﻤﺠﻤﻭﻋﺔ ﺍﻟﻀﺒﻁ ﺒﻴﻨﻤﺎ ﺍﻟﻘﺭﻓﺔ ﺘﺨﻔﺽ ﺍﻟﺠﻠﻜﻭﺯ ﻓﻰ ﺍﻟﺩﻡ ﻤﻌﻨﻭﻴﺎ ﻓﻲ ﻟﻲﺍﻷﻭ
  .ﺍﻟﺴﺎﻋﺔ ﺍﻟﺜﺎﻨﻴﺔ ﻭﻋﺩﺩﻴﺎ ﻓﻲ ﺍﻟﺴﺎﻋﺔ ﺍﻟﺭﺍﺒﻌﺔ
ﺭﺍﺒﻌﺔ ﻭﻋﺩﺩﻴﺎ  ﺍﻟﻘﺭﻓﺔ ﺘﺨﻔﺽ ﺍﻟﺠﻠﻜﻭﺯ ﻤﻌﻨﻭﻴﺎ ﻓﻲ ﺍﻟﺴﺎﻋﺔ ﺍﻟﺃﻥﻅﻬﺭﺕ ﺃ        ﺍﻟﺘﺠﺭﺒﺔ ﺍﻟﺜﺎﻨﻴﺔ ﺍﻟﻤﺠﻤﻭﻋﺔ   
  .ﺍﻟﺜﺎﻨﻴﺔ  ﻭﺍﻷﻭﻟﻲﻓﻲ ﺍﻟﺴﺎﻋﺔ 
 ﺍﻟﺴﻭﺩﺍﻨﻴﺔ ﻟﻬﺎ ﺍﺜﺭ ﺨﺎﻓﺽ ﻟـﺴﻜﺭ ﺍﻷﺴﻭﺍﻕ ﺍﻟﻘﺭﻓﺔ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﻤﺘﻭﻓﺭ ﻓﻲ ﺃﻥ        ﻭﻫﻜﺫﺍ ﻴﻤﻜﻥ ﺍﻟﻘﻭل 
ﻓﻰ ﺍﻟـﺩﻡ ﻓـﻲ   ﻟﻪ ﺃﺜﺭ ﺨﺎﻓﺽ  ﻟﻠﺠﻠﻜﻭﺯ ﻭﺃﻴﻀﺎﹰﺍﻥ ﺫﺍﺕ ﺍﻟﻤﺴﺘﻭﻯ ﺍﻟﻌﺎﻟﻰ ﻤﻥ ﺠﻠﻜﻭﺯ ﺍﻟﺩﻡ ﺫﺍﻟﺩﻡ  ﻓﻲ ﺍﻟﺠﺭ 
  .ﺍﻥ ﺫﺍﺕ ﺍﻟﻤﺴﺘﻭﻯ ﺍﻟﻌﺎﺩﻯ ﻤﻥ ﺠﻠﻜﻭﺯ ﺍﻟﺩﻡ ﻋﻨﺩﻤﺎ ﺘﻌﻁﻰ ﺒﺎﻟﻔﻡ ﺫﺍﻟﺠﺭ
 
1 
 
INTRODUCTION 
 
People using herbs for a therapeutic purpose in different parts of the 
world, and this behavior date back to immemorial times. Recently there is a 
very big attention to medicinal herbs, because of ready availability, their low 
cost of production and less toxic action compared to those of synthetic 
compounds (Asima and Pakrashi, 1995). 
There are multidisciplinary plant studies, covering: chemistry, 
pharmacology, biochemistry, microbiology, agential formation and clinical 
trial. In diabetes mellitus researches, there are so many experiments for using 
medicinal herbs in treatment of the two types of diabetes, for example using 
of Medicago sativa (Reem, 1999) and Pimpinella anisum (Fath ElRahman, 
2006). The study of cinnamon and its effect on diabetes mellitus carried out 
by Khan et al. (2003) showed the effect of Cinnamun cassia powder with type 
2 diabetes. The result of the study showed significant decrease in blood 
glucose of people with type 2 diabetes. 
Objectives: 
This study was undertaken to investigate: 
a.  The effect of oral administration of Cinnamun verum barks powder to 
hyperglycemic rats. 
b.  The effects of C. verum bark powder on normal glycemic rats.   
c.  To evaluate the effect of C. verum as antidiabetic to Glibenclamide as 
standard drug. 
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CHAPTER ONE 
LITERATURE REVIEW 
1.1 Pancreas: 
1.1.1 Pancreas gross anatomy: 
In man, the pancreas is an elongated organ located across the 
back of the abdomen, behind the stomach. The right side of the organ 
(called the head) is the widest part of the organ and lies in the curve of 
the duodenum (the first section of the small intestine). The tapered left 
side extends slightly upward (called the body of the pancreas) and end 
near the spleen (Kumar and Clark, 1988). 
1.1.2 Pancreas histological structure: 
The pancreas consists of exocrine and endocrine cells. The 
former are aciner cells, which are grouped into lobules forming the ductal 
system, which eventually point into the main pancreas duct. The 
endocrine pancreas consists of hormone-producing cells arranged in nets 
or islets of langerhans. They do not connect directly to the duct system 
(Kumar and Clark, 1988). 
1.1.3 Pancreatic function: 
The pancreas consists of very different organs contained within 
one structure. The acainer portion of the pancreas has an exocrine 
function, secreting into the duodenal lumen the enzymes and ions used 
for the digestive process. The endocrine portion consists of the islets of 
Langer hans’s. The pancreatic islets secret at least four hormones: 
insulin, glucagons, somatostatin, and pancreatic polypeptide (Robert      
et al., 1999). 
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1.2 Insulin: 
1.2.1 Structure and secretion: 
         Insulin is a polypeptide consists of two chains A and B. A chain 
consists of 21 amino acids, and B chain consists of 30 amino acids      
(Fig. 1). The two chains of A and B are linked by two intrachain disulfide 
bridges connect residues 6 and 11 of the A chain. Insulin is synthesized 
as preprohormone (molecular weight approximately 11,500), modified to 
proinsulin 9000-molecular weight and then to its mature structure, this is 
done by specific enzymatic cleavage. The proinsulin molecule is 
transported to the Golgi apparatus wherein proteolysis and packaging 
into the secretary granules begin. The human pancreas secretes 40-50 
units of insulin daily, which represent about 15-20% of the hormone 
stored in the gland. Insulin secretion is an energy requiring process that 
involves the microtubules microfilaments system in the B-cell of the 
islets (Robert et al., 1999). 
1.2.2 Factors affecting insulin release: 
1.2.2.1 Glucose: 
 The maximal response is obtained when glucose levels are 
between 300 and500 mg/dl. It is generally accepted that an increase of 
the ATP/ADP ratio result in the inhibition of ATP-sensitive potassium 
ion efflux channels. This causes depolarization of the B-cells and 
activation of voltage-sensitive calcium ion channels. The calcium ion 
influxes result in insulin secretion (Robert et al., 1999). 
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Fig. 1: Insulin structure, A and B chains linked by disulphide bonds. 
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1.2.2.2 Hormonal factor: 
        Numerous hormones affect insulin release, like: α - adrenergic 
agonist, B-adrenergic agonist, growth hormone, cortisol, placenta 
lactogen, estrogen and progestron. 
1.2.2.2.1 Probable actions of hormones countering the effect of 
insulin in man: 
         During an oral tolerance test, a mixed meal the first one-and-a-half 
hours are dominated by increased secretion of insulin, and both growth 
hormone and glucagon secretion are inhibited. Cortisol and adrenal 
hormones levels did not change significantly. 
Exercise represents a special stress with a rapid increase in the 
demand for metabolic fuel. At rest 90 % of the energy requirements of 
muscle come from oxidation of stored glycogen but, if the demand for 
oxygen outstrips supply, anaerobic glycolysis becomes all important. 
Glycogen supplies are rapidly depleted and glucose is extracted from the 
circulation independent of insulin. Blood glucose levels fall and secretion 
of insulin also decreases. Catecholamines and cortisol level rise, 
stimulating lipolysis and gluconeogenesis. The increase in hepatic 
glucose production matches the increased extrahepatic utilization so that 
glucose levels do not change markedly (Edward et al., 1995).    
1.2.2.3 Pharmacological agents: 
Many drugs stimulate insulin secretion, but the sulfonylurea 
compounds are used most frequently for therapy in human. Drugs such as 
tolbutamide stimulate insulin, release by a mechanism different from that 
employed by glucose and have achieved widespread use in the treatment 
of non insulin – dependent diabetes mellitus (type 1). A receptor that 
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binds this class of drugs has recently been cloned from the pancreatic B-
cell. This receptor is closely linked to the ATP-sensitive potassium ion 
channels described above, which may explain the mechanism of action of 
this important class of drugs (Robert et al., 1999). 
1.2.3 Insulin function: 
Insulin action includes membrane transport of glucose, amino 
acid and certain ions; formation of triglyceride; increase storage of 
glycogen; stimulation of DNA, RNA and protein synthesis. 
 1.2.3.1 The mechanism of insulin action: 
Insulin action begins when the hormone binds to specific 
glycoprotein receptor on the surface of the target cell. The diverse action 
of the hormone (Fig. 2) can occur within seconds or minutes. The insulin 
receptor is a hetrodimer consisting of two subunit, designated α and B, in 
the configure action α 2 B2, linked by disulfide bonds. Both subunits are 
extensively glycosylated, and removal of sialic acid and galactose 
decreases insulin binding and insulin action. Each of these glycoprotein 
subunits has a unique structure and function. The A subunit (5KDa) 
extracellular, and it bind insulin, probably via a cysteine-rich domain. 
The B subunit (95KDa) is transmembrane protein that performs the 
second major function of receptor. The cytoplasmic protein of the B 
subunit has tyrosine kinase activity and an autophosphorylation site 
(Robert et al., 1999). Recently the work from several laboratories 
described the cellular life cycle of the IR, shown schematically in Fig. (2) 
in five cellular compartments (colored blocks).  
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Fig. 2: Insulin binding its receptor and the mechanism of action. Life 
cycle of the insulin receptor, it is shown as four parallel lines. 
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Receptor internalization is also triggered by insulin binding. 
Insulin is removed from circulation by the IR, through endocytosis 
(Terris et al., 1979). 
1.3 diabetes mellitus: 
Diabetes mellitus is a syndrome characterized by chronic 
hyperglycemia that results from insulin deficiency or resistance or both 
(Kumar and Clark, 1988). 
1.3.1 Diabetes mellitus in domestic animals: 
Diabetes mellitus is frequently found in the dog (1 in 152), and 
cats (1 in 800), although it has been reported in horse, cattle, sheep and 
pigs. The fundamental defect in domestic animals is an absolute or 
relative lack of insulin. As a result of this deficiency in insulin, the 
animal is unable to utilize glucose. Consequently hyperglycemia is 
constant finding in diabetic animals. Clinical signs typically associated 
with diabetes include polydipsia, polyurea, increase appetite and weight 
loss. The classic signs of ketosis include anorexia; vomiting, weakness, 
lethargy and increase respiratory rate (Coles, 1986). 
1.3.2 Diabetes mellitus in man: 
 Diabetes mellitus affects more than 30 million people world wide 
(Kumar and Clark, 1988). In 1993 there were 7.8 million diagnosed cases 
of diabetes in the United State, of whom 43 % were treated with insulin. 
Insulin dependent diabetes mellitus (IDDM) with onset at age < 30 years 
comprises 7% of all diagnosed cases.  
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  Some studies indicate that 7 % of insulin-treated cases with onset 
at age ≥ 30 years may also be IDDM. Impaired glucose tolerance (IGT) is 
a class that encompasses persons whose glucose tolerance is intermediate 
between normal and diabetic. About 11% of adults have IGT when tested 
by oral glucose challenge (Michael et al., 1997). 
1.3.3 Classification of diabetes mellitus: 
Most patients can be classified clinically as having either insulin- 
dependent diabetes mellitus (IDDM or type1) or non insulin-diabetes 
(NIDDM or type11). In 1979, the national diabetes data group formally 
classified diabetes mellitus and other categories of glucose intolerance as 
follows:- 
1.3.3.1 1nsulin dependent diabetes mellitus (IDDM or type1): 
         About 10% of diabetic patients are insulin dependent diabetes 
mellitus.Type1 diabetes is a usually results when the body’s own immune 
system launches a misguided attack on the insulin-producing beta cells in 
the pancreas. Harmful immune system cells, including some T cells, are 
normally eliminated during their maturation. However, in susceptible 
individuals, this disease – causing T cells initiate an inflammatory 
process in the pancreas that eventually leads to the destruction of beta 
cells. The other arms of immune system – the B cells – produce 
antibodies that also recognize beta cell protein (Dorman et al., 1995). 
         Type 1diabetes may develop in persons with a family history of 
type 1 diabetes, but may also develop in persons with no family history 
of diabetes. In either case, the person has one or more genes that make 
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them susceptible to the disease. Environmental factors, such as exposure 
to certain viruses and foods early in life, may trigger the autoimmune 
response (Edward et al., 1995). 
1.3.3.2 Non-insulin-dependent diabetes mellitus (NIDDM or type2): 
        About 90% of persons with diabetes are non-insulin dependent 
diabetes mellitus (type 2) patients, such patients are usually obese, have 
elevated  plasma insulin level, and have down regulated insulin receptors 
(Robert et al., 1999).The pathogenesity of type2 diabetes is complex and 
involves the interaction of genetic and environmental factors (Henry      
et al., 2007). Environmental factors, genetic factors, age, pancreatic 
pathology and pregnancy may contribute in the development of type 2 
diabetes mellitus. 
1.3.3.2.1 Environmental factors: 
        Particularly excessive caloric intake and sedentary lifestyle lead to 
obesity. The clinical presentation is also heterogeneous with a wide range 
in age of onset. Severity associated with hyperglycemia, and degree of 
obesity. From a pathophysiologic standpoint, person with type2 diabetes 
constantly showed three cardinal abnormalities: (1) resistance to the 
action of insulin in peripheral tissue, particularly muscle and adipose 
tissue but also liver; (2) defective insulin secretion, particularly in 
response to glucose stimulus; and (3) increase glucose production by the 
liver. 
1.3.3.2.2 Genetic factor in the developing type2 diabetes: 
Generally type 2 diabetes consists of monogenic and polygenic 
forms. The monogenic form is uncommon disorder. 
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I.3.3.2.2.1 Monogenic forms of diabetes associated with insulin 
resistance: 
More than 70% mutations have been identified in the insulin-
resistance patients. These mutations may impair receptor function by a 
number of different mechanisms, including decreasing the number of 
receptors expressed on the cell surface e.g. by decreasing the rate of 
receptor biosynthesis (class1), accelerating the rate of receptor 
degradation (class5), or inhibiting the transport of receptors to the plasma 
membrane (class2). The intrinsic function of the receptor may be 
abnormal if the affinity of insulin binding is reduced (class3) or receptor 
tyrosine kinase is inactivated (class4). The insulin resistance that is 
associated with insulin receptor mutations may be severe and present in 
the neonatal period, as with leprechaunism and Rabson Mendenhall 
syndrome, or occur in a milder form in adulthood leading to insulin-
resistant diabetes with marker hyperinsulinemia, acanthosis nigricans, 
and hyperandrogenism (Henry et al., 2007). 
1.3.3.2.3 Age: 
        In Britain over 70% of all cases of diabetes, occur after the age of 50 
year. In contrast IDDM which mainly affects younger people, NIDDM is 
principally a disease of the middle –aged and elderly. Thus, aging is an 
important risk factor for NIDDM (Edward et al., 1995). 
1.3.3.2.4 Pregnancy: 
During normal pregnancy, the level of plasma insulin is raised by 
the action of placental hormones, thus placing a burden in insulin- 
secreting cells of the pancreatic islet. The pancreas may be unable to 
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meet these demands in women genetically predisposed to develop both 
types of diabetes. Repeated pregnancy may increase the likelihood of 
developing permanent diabetes, particularly in obese women. Long-term 
studies showed that some 80% of women with gestational diabetes 
ultimately develop permanent clinical diabetes requiring treatment 
(Edward et al., 1995). 
1.3.3.2.5 Pancreatic pathology and insulin secretion: 
          In contrast to IDDM where at diagnosis the insulin- secreting cells 
have largely disappeared from the pancreas so that plasma 
immunoreactive insulin is either very low or undetectable, in NIDDM 
there is only moderate reduction in the total mass of islet tissue consistent 
with a measurable, though, when related to the blood glucose level, and 
reduced concentration of insulin in plasma. There are, however, some 
pathological changes, which are typical of NIDDM and demonstrable in 
most, although not all cases. The most consistent of these changes is 
probably deposition of amyloid which is accompanied by atrophy of the 
normal tissue, particularly islet epithelial cells. In more advanced lesion, 
the islet is more or less converted to amyloid and the reduction in the 
number of insulin-secreting cells is more pronounced than that of 
glucagon-secreting-cells. Deposition of amyloid is probably not a cause 
of diabetes but rather reflects a pathological process which is increased in 
NIDDM (Edward et al., 1995). 
 1.3.3.2.6 Insulin resistance and the risk of type2 diabetes: 
The term insulin resistance indicates the presence of an impaired 
biologic response to either exogenously administered or endogenously 
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secreted insulin. Insulin resistance is manifested by decreased insulin-
stimulation glucose transport and metabolism in adipocytes and skeletal 
muscle and by impaired suppression of hepatic glucose out put. Insulin 
sensitivity is influenced by a number of factors including age, weight, 
ethnicity, body fat (especially abdominal), physical activity, and 
medication (Henry, .2007). 
1.3.3.2.7 Obesity and type2 diabetes: 
         The absolute amount of body fat has an effect on insulin sensitivity 
across a broad range. Elevated free fatty acids (FFAs) predict the 
progression from impair glucose tolerance test to diabetes. In the 
periphery, free fatty acids may not be markedly elevated because of 
efficient extraction by the liver and skeletal muscle. Increases in fatty 
acid flux to skeletal muscle related to the increase visceral lipolysis have 
been implicated in the inhibition of muscle glucose up take. The Randle 
hypothesis, or glucose fatty acid cycle, was originally proposed to 
account for the ability of free fatty acids to inhibit muscle glucose 
utilization. Randle and co-workers (1966) demonstrated that fatty acids 
compete with glucose for substrate oxidation in isolated muscle. The 
increase in fatty acid metabolism leads to an increase in the intra 
mitochondrial acetyl Co enzyme A (Co A); Co A and reduced 
nicotinamide, NADH/NAD ratios with subsequent inhibition of puruvate 
dehydrogenase. The resulting increased intercellular mitochondrial (and 
cytosolic) citrate concentration result in allosteric inhibition of 
phosphofructokinase, the key rate controlling enzyme in glycolysis. The 
subsequent accumulation of glucose 6 phosphate would inhibit 
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hexokinase II activity, resulting in an increase in intercellular glucose 
concentrations and decrease glucose up take (Michael et al., 1997). 
 1.3.4 Intermediate risk categories: 
1.3.4.1 Impaired glucose tolerance (IGT): 
Impaired glucose tolerance (IGT) is defined as glycemic response 
to the standard 75g oral glucose challenge that is intermediate between 
normal and diabetic i.e. venous plasma or capillary whole blood glucose 
concentration 140-199mg/dl at 2 hour after a glucose load. The incidence 
of the IGT was reported to be 17.6 per 1,000 person-years in non 
Hispanic whites and 32.6 per 1,000 person- years in Hispanic. The 
importance of the IGT as a prognostic category for development of 
NIDDM is generally accepted, but some aspects remain controversial 
(Michael et al., 1997). 
1.3.4.2 Potential abnormality of glucose tolerance (Pot AGT): 
Person who have never exhibited abnormal glucose tolerance but 
who are at substantially increased risk for the development of IDDM and 
NIDDM are well established, such as being a relative of an IDDM or 
NIDDM diabetic or belonging to certain ethnic or racial group, although 
the degree of risk for any of the specific circumstances is much less clear. 
1.3.5. Biochemical changes associated with diabetes mellitus: 
Lack of insulin causes significant disturbance of carbohydrate, 
protein and fat metabolism (Kumar and Clark, 1988). 
1.3.5.1 Disturbance in carbohydrate metabolism: 
The disturbance in carbohydrate metabolism is due to the fact 
that the liver and skeletal muscles cannot store glycogen and the muscles 
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are unable to utilize glucose. When the kidney threshold for glucose is 
exceeded, glucouria occurs with consequent increase of water excretion 
and disturbance of electrolyte and water balance. 
1.3.5.2 Disturbance in protein metabolism: 
Protein metabolism in the liver is also deranged and an excessive 
amount of protein is transformed into carbohydrate (Wilson et al., 1975). 
1.3.5.3 Disturbance in fat metabolism: 
In addition, the amount of fat metabolized by the diabetic patient 
is excessive, and since normal fat catabolism can only proceeds at a 
limited rate, ketone bodies are present in the blood and the urine in much 
large amount than normally; these substances are excreted in the urine as 
β-hydroxybutaric acid and acetoacetic acid and as acetone in the breath 
(Wilson et al.,1975).The liver produces ketone bodies by oxidation of the 
free fatty acids and this decreases the production of ketone bodies, 
conversely, glucagons stimulates ketone body production by stimulating 
lipolysis and increasing fatty acid oxidation. In the diabetes patient, 
particularly with type1 diabetes, the consequences of insulin deficiency 
and glucagons excess provide a hormonal milien that favors ketogenesis 
and in the absence of appropriate treatment, may lead to ketoneamia and 
acidosis. Insulin also interacts with the capillary endothelium to activate 
lipoprotein lipase, the enzyme that hydrolyses the triglycerides present in 
very-low-density lipoprotein VLDL and chylomicrons, resulting in 
release of intermediate-density lipoprotein ILD particles (Taskinen, 
1985). These ILD particles are converted by the liver to the more 
cholesterol- rich- density LDL. In the untreated or under treated diabetic 
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patient, hypertriglycridemia may occur as a result of the decrease 
removal of VLDL secondary to decrease activity of lipoprotein lipase. In 
addition, deficiency of insulin may be associated with increased 
production of VLDL (Gilman et al., 1992). 
1.3.5.4 Pathological complication of diabetes mellitus type 2: 
Type 2 may go unnoticed for years in a patient before 
diagnosis, since the symptoms are typically milder (no ketoacidosis) 
and can be sporadic. However, severe complications can result from 
improperly managed Type 2 diabetes. The case of diabetic 
complication is not known and may be multifactorial. Major emphasis 
has been placed to sorbitol by the enzyme adol reductase. Sorbitol 
which appears to function as a tissue toxin, has been implicated in the 
pathogenesis of retinopathy, neuropathy, cataracts, nephropathy and 
artic disease. The mechanism is perhaps best worked out in 
experimental diabetic neuropathy, where sorbitol accumulation is 
associated with a decrease in myoinsitol content, abnormal 
phosphoinositide metabolism, and decrease in Na, K ATPase activity. 
Second mechanism of potential pathogenic importance is 
glycation for non enzymatic addition of hexoses to proteins and 
glycosylation for enzymatic addition. The effect of such glycation on 
hemoglobin is important in monitoring the control, but multiple 
proteins in the body are altered in the same way, often with disturbed 
function. Examples include plasma albumin, fibrin, collagen, 
lipoproteins and the glycoprotein recognition system of hepatic 
endothelial cell (Harrison, 1996). 
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1.3.6. Therapy for diabetes: 
The most recent information reported the use of diet, oral agent, 
and insulin by people with diabetes mellitus (Michael et al., 1997). 
1.3.6.1 Nutritional therapy: 
Nutritional therapy is a challenging but necessary dimension in 
the management for all types of diabetes. For children with IDDM, a goal 
is to match diet with insulin requirements to ensure normal growth and 
development. According to current guidelines, dietary protein intake 
should constitute 10-20% of total daily calories. Saturated and 
polyunsaturated fat should each be limited to <10% of total daily calories 
and the remaining 60-70% of calories, composed of monounsaturated fat 
and carbohydrate. Cholesterol should be limited to ≤ 300 mg daily 
(Michael et al., 1997). 
1.3.6.2 Pharmacological treatment: 
There are so many drugs in treatment of type 2 diabetes like:-  
1.3.6.2.1 Meglitinides: 
  Meglitinides help the pancreas to produce insulin and are often 
called "short-acting secretagogues." Their mode of action is original, 
affecting potassium channels (Rendell, 2004). By closing the potassium 
channels of the pancreatic beta cells, they open the calcium channels, 
hence enhancing insulin secretion (Eurich et al., 2007). 
1.3.6.2.2 Peptide analogs: 
Incretin mimetics: 
Incretins are insulin secretagogues. The two main candidate 
molecules that fulfill criteria for being an incretin are Glucagon-like 
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peptide-1 (GLP-1) and Gastric inhibitory peptide (aka glucose-dependent 
Insulinotropic peptide or GIP). Both GLP-1 and GIP are rapidly 
inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) (Thorens, 
1995). 
1.3.6.2.3 Glucagon-like peptide (GLP) analogs: 
GLP agonists bind to a membrane GLP receptor as a consequence 
of this, insulin release from the pancreatic beta cells is increased. 
Endogenous GLP has a half life of only a few minutes; thus an analogue 
of GLP would not be practical (Eurich et al., 2007). 
1.3.6.2.4 Thiazolidinediones: 
Thiazolidinediones (TZDs), also known as "glitazones," bind to 
PPARγ, a type of nuclear regulatory proteins involved in transcription of 
genes regulating glucose and fat metabolism. These PPARs act on 
Peroxysome Proliferator Responsive Elements (PPRE). The PPREs 
influence insulin sensitive genes, which enhance production of mRNAs 
of insulin dependent enzymes. The final result is better use of glucose by 
the cells (Eurich et al., 2007). 
1.3.6.2.5 Glibenclamide: 
Also known as glyburide, is an anti-diabetic drug in a class of 
medications known as sulfonylureas, used in the treatment of type II 
diabetes, it is one of only two oral anti-diabetics in the World Health 
Organization Model List of Essential Medicines (the other being 
metformin). It is also sold in combination with metformin under the trade 
name (Marcha, 2007). 
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1.3.6.2.6 Glucovance: 
Glucovance is a drug works by inhibiting ATP-sensitive potassium 
channels in pancreatic beta cells. This inhibition causes cell membrane 
depolarization, opening of voltage-dependent calcium channels, thus 
triggering an increase in intracellular calcium into the beta cell which 
stimulates insulin release(Monami et al., 2006). 
1.4 Medicinal plants: 
    Because of the ready availability of the medicinal herbs, their low 
cost of production and less toxic action compared to those synthetic 
compounds, the World Health Organization has been advocating the use 
of traditional remedies. Multidisciplinary plant studies, covering 
chemistry, pharmacology, biochemistry, galenical formulation, 
standardization, clinical trials and production technology have resulted in 
technical processes being developed for production, semi finished 
products and medicaments from indigenous medical plants. 
Phytochemical studies, one of the advances in research and application of 
modern technical method, which determined the chemical composition of 
medicinal plants so as to identify the active chemical ingredient (Asima 
and Pakrashi, 1995). 
Recently, many experimental and clinical trials were made to 
detect the hypoglycemic and anti-diabetic effects of many medical plants 
used in the medicine for the treatment of diabetes mellitus 
(FathElrahman, 2006).  
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1.4.1 Cinnamomum verum: 
Cinnamon considered more precious than gold, in the recent 
studies in medical herbs. During this time, cinnamon received attention 
in china, evidenced by its inclusion in one of the earliest books on 
Chinese botanical medicine, dated around 2700B.C. even today, 
Cinnamon is considered one of 50 Chinese fundamental medicinal herbs 
(WHFoods, 2007). 
1.4.1.1 Classification of Cinnamomum verum: 
Kingdom: Plantae. 
Division: Magnoliphyta.  
Class: Magnolipsida. 
Order: Laurales. 
Family: Lauracae. 
Genus: Cinnamomum. 
Species: Cinnamomum verum J.s.Persl. 
Synomons names: Cinnamomum zeylanicum. 
English names:-Cinnamon, Ceylon Cinnamon, Chinese cinnamon. 
Arabic name: Algerfa. 
1.4.1.2 Plant origin: 
The member of the family Lauracae can be found throughout 
tropical and subtropical regions of the world, Primary in the lowland to 
mountains rain forests. The main centers are in Southeast Asia and 
tropical America. Lauracae family includes about 32 genera, and 2500 
species (Heywood et al., 1971). Cinnamomum cassia (Fig. 4) was 
founded in China, species closely related to Cinnamomum verum  
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1.4.1.3 Plant description: 
 Cinnamon, Cinnamomum spp, is an aromatic spice isolated from 
the inner bark of cinnamon trees (Fig. 3). Which is a green tree all the 
seasons of the year, its height about 12 miters and it has horizontal 
branches, simple and ovate leaves, yellow or white flowers (Fig.4, 5) and 
its fruit is globe or ovate shaped coumarin (Elgazali  et al., 1998). 
1.4.1.4.1 Active ingredients of Cinnamomum verum: 
 Cinnamomum spp. bark contains: between 0.5-4% essential oil 
containing 80% cinnamaldehyde, up to 10% eugenol and 5-10% trans-
cinnamic acid; 4-10% phenolic compounds; condensed tannins; 
catechins; oligomeric proanthocyanidins; other monoterpenes including 
limonene and alpha-terpinol; sesquuiterpenoid including pinene; calcium 
monoterpenoid oxalate; gum; mucilage; resin; starch; sugar; and traces of 
coumarin (Mancini et al.,1998).  
1.4.1.5 Biological activities: 
1.4.1.5.1 Antimicrobial effect of cinnamon: 
The antimicrobial effect of Cinnamomum sp was identified in a 
laboratory experiment in which pure Cinnamomum cassia extract, 
mainly composed of the active ingredient cinnamaldehyde, was tested 
on isolated strains of bacteria, including Gram-positive Staphylococcus 
aurus, gram-negative Escherichia coli, Enterobacter aerogenes, 
Proteus vulgaris, Pseudomonas aeruginosa, Vibrio cholerae, Vibrio 
parahaemolyticuas, and Samonella typhymurium. 
          The antimicrobial effect resulted in a minimum inhibition 
concentration (MIC) of Cinnamomum cassia extract ranging from 75 
mcg/mL  to  600  mcg/mL on  these  various  bacteria  (Ooi et al., .2006).  
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Fig. 3: Cinnamomum verum bark 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Cinnamomum cassia (flowering plants) 
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Fig. 5: Cinnamomum verum (flowering plants) 
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However, conflicting data was obtained in a randomized, controlled pilot 
clinical trial of 15 patients ages 16 to 79 who had a positive 
Campylobacter urease test for Helicobacter pylori. Each patient in the 
control group received 40 mg of ethanol extract of cinnamon twice daily 
for four weeks; the control group received plain 95% ethanol. With urea  
breath  tests as  the  measurement of efficacy, the mean urea breath test 
before and after the study for the treated group were 22.1 and 24.4, 
respectively; the mean urea breath test before and after the study for the 
controlled group were 23.9 and 25.9, respectively. This conclusive study 
found that 40 mg of cinnamon extract given twice dialy was ineffective 
in eradicating Helicobacter pylori (WHFoods, 2007; Nir et al., 2000). 
1.4.1.5.2 Anti-inflammatory: 
Although Cinnamon historically had not been used to treat 
inflammatory disorders, its anti-inflammatory effect was demonstrated 
experimentally. Specifically, Cinnamomum cassia was used to 
investigate the anti-inflammatory effect on nitric oxide (NO) and 
nuclear factor kappa-b. Both substances have been implicated in 
inflammation. In acute and chronic inflammation, there is an increased 
production of NO, which promotes vasodilatation and results in 
increased vascular permeability and edema. Nitric oxide also activates 
COX-2 enzyme involving in the biosynthetic pathway of inflammatory 
prostaglandins (Thomas et al., 2004). Nuclear factor kappa-b 
contributes to inflammation through induction of transcription of genes 
coding for inflammatory mediators. It was found that cinnamaldehyde, 
specifically 2'-hydroxycinnamaldehyde found in Cinnamomum cassia 
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extract, exhibited a dose-dependent inhibitory effect on NO production 
and transcriptional activity of NF-kB, thereby contributing to its anti-
inflammatory qualities (Lee et al., 2005). 
1.4.1.5.3 Antifungal: 
Cinnamon oil has been reported as an antifungal agent, 
although current efficacy of cinnamon oil's fungicidal effect has not 
been tested in clinical trials.   
Experimentally, promising results on its antifungal activity were 
reported in two invitro studies of cinnamon oil on Cryptococcus 
neoformans and Aspergillus niger. Cryptococcus neoformans is an 
opportunistic fungal pathogen affecting the lungs or meninges of 
immunocompromised or AIDS patients, causing pulmonary 
cryptococcosis meningitis (Lee et al., 2005). It was found that the 
phenolic compound in cinnamon oil identified as eugenol is responsible 
for its fungitoxic activity (Viollon and Chaumont, 1994). Cinnamon oil's 
antifungal property was again demonstrated in a more recent in vitro 
study on Aspergillus niger (A. niger), an opportunistic fungal pathogen 
residing in the air and, through inhalation of Aspergillus sp. spores, 
entering the respiratory tract of patients with AIDS or with 
immunocrompromised conditions to cause Aspergillosis (Beers and 
Porter, 2006). Seventy- Cinnamomum cassia, were tested for the 
inhibition of five botanical essential oils, including Cinnamomum 
zeylanicum and hyphal growth and spore formation on inoculated agar 
with A. niger incubated at 28oC for 48 hours. Among the 75 botanical 
essential oils used, Cinnamomum zeylanicum and Cinnamomum cassia 
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demonstrated maximal and superior results; the zone of hyphal growth 
inhibition and zone of spore formation were 43 and 40 versus 50 and 45 
for Cinnamomum zeylanicum and Cinnamomum cassia, respectively 
(Pawar and Thaker, 2006). 
1.4.1.5.4 Antioxidant: 
There is more to cinnamon besides the antimicrobial, anti-
inflammatory, and antifungal effects attributed to cinnamaldehyde found 
in Cinnamomum cassia powder and oil. The presence of oligomeric 
proanthocyanidins (OPC), a class of bioflavonoid, opened a new area of 
research on its antioxidative effect. Through agriculture research, type A 
and type B oligomeric proanthocyanidins were identified in cinnamon 
spice via mass spectrometer analysis. Additionally, it was found that over 
84% to 90% of OPC found in cinnamon spice were type A OPC (Gu      
et al., 2003). However, there has not been a specific study on the 
antioxidative effect of cinnamon alone. Antioxidants are essential to the 
human body to neutralize free-reactive oxygen species, also known as 
free radicals, to maintain functional cellular membrane and structure. 
Furthermore, free radicals associated with impaired glucose metabolism 
and antioxidants have been implicated in the regression of diabetes 
mellitus. 
1.4.1.5.5 Hypoglycemic effect of Cinnamomum sp: 
 The quest for new treatments continues as the realm of research 
for type 2 diabetes expands to nutraceutical products. A pilot clinical trial 
conducted in Pakistan to study the effect of cinnamon in patients with 
type 2 diabetes harvested successful results. The study involved 60 
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subjects (30 men and 30 women) with type 2 diabetes, average age of 
52.2±6.32 years, fasting plasma glucose of 140-400 mg/dL, and not 
taking insulin or medicines for other health conditions. Subjects were 
randomly assigned into three placebo groups and three cinnamon groups 
in which they were given 1, 3, or 6 g of cinnamon capsules 
(Cinnamomum cassia powder) daily for 40 days followed by a 20-day 
wash-out period. All subjects were allowed to continue taking 
sulfonylurea drugs during the study. Plasma glucose, triglyceride, low-
density lipoprotein (LDL), high-density lipoprotein (HDL), and total 
cholesterol were measured at fasting state before and after treatment. 
Effects were similar among the three cinnamon-treated groups. The mean 
reduction in blood glucose, triglyceride, LDL, and total cholesterol levels 
were 18–29, 23–30, 7–27, and      12–26%, respectively; changes in these 
levels were not significant in the placebo groups as well as HDL levels 
for all six groups. Interestingly, the effects of cinnamon lingered on after 
discontinuation. Khan et al. (2003). reported that plasma glucose, 
triglyceride, LDL, and total cholesterol levels continued to remain lower 
than baseline during the 20-day wash-out period. Khan et al. (2003) 
suggested that daily consumption of cinnamon may not be necessary due 
to the observed sustained effects of cinnamon in studied subjects with 
type 2 diabetes and that inclusion of cinnamon into daily diet may be 
beneficial to the remainder of the population. 
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CHAPTER TWO 
MATERIALS AND METHODS 
This work has been conducted in the Department of  
Pharmacology in Medicinal and Aromatic Plants Institute (MAARI), 
Sudan National Center for Research.  
2.1 Material 
2.1.1 Experimental Animals 
 Charles Foster strain white albino rats divided to five groups, 
each group consisted of six rats, their body weight between (150-200g), 
were used for all experiments. Rats used in all experiments were kept on 
a fixed diet so as to stabilize the fasting serum glucose. 
2.1.2 Feeding 
Each group was kept in a cage and was supplied with feed 
composed of meat, wheat flour, carrot and salt. The feed was available at 
the rate of 36 g per day in each cage. 
2.1.2.1 Chemical analysis of the rat diet 
- Dry matter    97.22% 
- Ash     3.82% 
- Crude  protein    7% 
- Crude  fibre   5.61% 
- Nitrogen free extract   73.21% 
- Fat      7.52%  
The analysis of the diet was made at the Department of Animal 
Nutrition, Faculty of Animal Production, U. of K., Sudan. 
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2.1.3 Plant material: 
  The Cinnamomum verum bark was bought from Khartoum Bahry 
market. Dry bark of Cinnamon was ground to powder. 
2.2.3 Experimental protocol: 
        Experimental design of experiment 1 is shown in table 1and 
experimental design of experiment 2 is shown in table 2. 
Experiment 1: 
2.1.3.1. Induction of hyperglycemia in rats: 
Albino rats in group A, B and C were kept fasting for 18 hours. 
The serum glucose level was determined at zero hour. Immediately after 
that 50% of glucose solution was injected interaprotonially at dose of 
2g/kg Bwt so as to induce hyperglycemia. 
2.1.3.2. The effect of oral administration of Cinnamomum verum 
bark  on serum glucose level of hyperglycemic rats:    
Group A: 
 After induction of hyperglycemia, the serum glucose level of the 
animals was measured at 1 hour, 2hour and 4 hour after glucose load. 
Group B:  
 After induction of hyperglycemia, Glibenclamide, standard 
antidiabetic drug was given per os at a dose of 10mg/kgBwt. The glucose 
was then measured at 1hour, 2hour and 4 hour. 
Group C: 
  After inductions of hyperglycemia, cinnamon bark powder mixed 
with distilled water was given orally at a dose of 1g/kg Bwt. The plasma 
glucose level of the animals was measured at 1 h, 2h and 4 h. 
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Table No 1: The experimental design of experiment (1). 
Groups 
Description 
A B C 
Numbers of rats 6 6 6 
Induction of hyperglycemia + + + 
Treatment - Glibenclamide C. verum 
 
 
 
Table No 2: The experimental design of experiment (2). 
 
  
 
Group 
Description 
D E 
Number of rats 6 6 
Induction of hyperglycemia - - 
Treatment - C. verum 
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Experiment2: 
2.1.3.4 The effect of the oral administration of Cinnamomum verum  
  bark powder on serum glucose level of normoglycemic rats: 
Group D: 
       Group D was kept fasting for 18 hours. The glucose was then 
measured at zero, 1, 2 and 4h after fasting. 
Group E: 
        Albino rats of group E were kept fasting 18 hours. The serum 
glucose level was measured at zero h, immediately after that 
Cinnamomum verum bark powder mixed with distilled water was given 
orally at a dose of 1g/kg Bwt. The plasma glucose level of the animals 
was then measured at 1, 2, and 4 h following treatment. 
2.1.4 Sample collection:  
 In all groups, blood was drawn out by capillary tube in sterile test 
tubes from the orbital plexus of rats under inhalation anesthesia using 
halothane according to Khana, (1992). The collected blood was allowed 
to clot and then centrifuged at 300 r p m for 5 minuets to separate serum. 
The prepared serum was used to estimate, glucose. 
 2.1.5 Chemicals and reagents: 
       Glucose’s kit of Crescent Diagnostic laboratories was used.   
2.1.6 Instruments: 
* IEC-CENTRA-4B centrifuge. 
* Finn pipettes, digital micropipette was used for pipetting serum 
 samples and reagent. 
* Sterile plain test tubes, was used for collection of blood. 
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* CIBA CORNING colorimeter model 252 were used to estimate 
 glucose. 
2.2 Methods:  
2.2.1 Glucose oxidase method: GOD/PAP: 
 Glucose concentration in the serum was determined by enzymatic 
colourimetric, GOD-PAP method (Trinde, 1969).  
Principle: 
Glucose is determined after enzymatic oxidation in the presence of 
glucose oxidase. The hydrogen peroxide formed reacts under catalysis of 
peroxidase, with phenol and 4-aminophenazone to form a red violet 
quinoneimine dye as indicator.  
Reaction principle: 
1. α-D-Glucose  mutarotase   β-D glucose. 
2. β-D glucose+ H2O + O2    GOD    D-gluconic acid + H2O2. 
3. H2O2 + 4 aminophenazone + phenol   POD  quinonemine + 4 H2O. 
Reagent composition: 
Crescent Diagnostic, reagent (Cat No.CS605s) was used. It is 
composed of: 
1. Phosphate buffer (pH 7.5) 0.1 mol/l 
* Aminophenazone 0.25 mmol/l 
* Phenol  0.75 mmol/l 
* Glucose oxidase  15 KU/l 
* Peroxidase   1.5 KU/l 
* Mutarotase  2 KU/l 
2. Glucose standard 100mg/dl or 5.5mmol/l  
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Procedure: 
A volume of 0.01µl of each standard, sample and distilled 
water was pipitted each in separate cuvettes, 1µl of the reagent was added 
to each cuvettes, mixed well and incubated for 10 minutes at 20-25oC or 
37 ۫۫oC. The absorbance of the standard Astd and of the sample As were 
measured against the reagent blank at the wave length 546-500 nm.  
Calculations: 
As Glucose (mg/dl) = Astd 
X concentration of standard 
 
2.2.4 Statistical design: 
According to completely randomized design, the rats of 
experiment 1 and 2 were divided into three groups and two groups 
respectively. Each group contains 6 rats of similar body weight. The data 
were analyzed by statistical package for social scientists (SPSS) and T- 
test. Each test was conducted at 5% level of significance.      
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CHAPTER THREE 
RESULTS 
Experiment 1 
3.1 The effect of oral administration of Cinnamomum verum and 
Glibenclamide on serum glucose level of hyperglycemic rats 
  When C. verum and Glibenclamide were administrated orally to 
fasting rats of group B and C, the serum glucose level measured after 
18 hours fasting and then at 1, 2 and 4 hours after glucose loading are 
shown in Table (3) and Fig. (6). 
  At 0 h, there was no significant difference in glucose level 
between the treated groups (B and C) and the control group (A) as 
shown in Table (3) and Fig. (6). 
   At hour 1after glucose loading, the serum glucose level of 
Glibenclamide treated rats group (B) was significantly (P≤ 0.0007) 
lower than control group (A) and C. verum treated group (C). But, the 
serum glucose level of C. verum treated group (C) was nonsignificantly 
higher than that of control group (242.08 Vs 208.58), as shown in Table 
3 and Fig. 6. 
   At 2h after glucose loading the glucose level of both treated 
group (B and C) were significantly lower (P≤0.001) than that of control 
(Table 3, Fig. 6) and the glucose level of Glibenclamide treated group 
was nonsignificantly lower  than that of  C. verum treated group C. 
   When serum glucose was measured at hour 4, the glucose level 
of group B was significantly (P≤0.002) than that of C. verum treated 
group (C) and the control group (A), also the glucose level of C. verum  
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Table (3): The effect of oral administration of C. verum and Glibenclamide 
on serum glucose level of an induced hyperglycemic rats. 
 
Blood glucose  concentration (mg/ dl) of groups: Sampling 
Time A B C 
P 
0 h 91.57±8.32 a 89.52±6.98 a 111.17±14.05 a 0.2868 
1 h 208.58±23.85 a 92.49±7.00 b 242.08±30.21 a 0.0007 
2 h 185.83±15.73 a 78.05±5.61 b 109.25±23.42 b 0.0011 
4 h 142.67±15.50 a 74.92±5.47 b 125.25±11.37 a 0.0024 
(Data are expressed in mean ± SE) 
 
Mean values having different superscript small letters within same row 
differ significantly at (P≤0.05). 
Group A: Hyperglycemic untreated rats. 
Group B: Hyperglycemic treated with Glibenclamide.   
Group C: Hyperglycemic treated with C. verum.  
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Fig. 6: The effect of C. verum and Glibenclamide on serum glucose level of 
hyperglycemic rats as shown by glucose tolerance test.  
    Bars with different letters are significantly different (P≤0.05).  
Group A: Hyperglycemic untreated rats. 
Group B: Hyperglycemic treated with Glibenclamide.  
Group C: Hyperglycemic treated with C. verum.  
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treated group C was nonsignificantly lower than the glucose of the control 
group A (125.67 Vs 125.25) as shown in Table (3) and Fig. (6). 
Experiment 2 
3.2 The effects of oral administration of C. verum on serum glucose level 
of normoglycemic rats: 
 When the serum glucose level of normoglycemic fasting rats 
was measured after 18 hours fasting (0h) and then at 1, 2 and 4 hours 
after administration of C. verum at a dose of 1g/kgBwt to group E rats, 
the serum glucose level of the control group (D) and treated group (E) 
are shown in Table (4) Fig. (7).  
 Results showed that there was a decrease non-significantly in 
serum glucose concentration at hour1and 2 in group E when compared 
to the control group (D).   
       However, the serum glucose level of C. verum treated rats (group 
E) was significantly lower when compared to control at the hour 4. 
 It was also observed that the serum glucose level of C. verum 
treated rats decreased gradually after administration of C. verum while 
the serum glucose level of the control remained almost constant 
throughout the experiment.  
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Table (4): The effects of administration of C.verum on serum glucose level 
of normoglycemic rats. 
Serum glucose  concentration 
(mg/ dl) of group: Sampling 
Time D E 
P 
0 h 90.36±1.88a 95.64±13.92a 0.73 
1 h 95.59±7.67a 88.92±4.62a 0.66 
2 h 97.03±4.34a 80.10±7.33a 0.09 
4 h 96.56±4.37a 73.65±5.08b 0.01 
(Data are expressed in mean ± SE) 
Mean values having different superscript small letters within same row differ 
significantly at (P≤0.05). 
Group D: Normoglycemic untreated rats. 
Group E: Normoglycemic treated with C. verum. 
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Fig. 7: The effects of administration of C.verum on serum glucose level of 
normoglycemic rats.  
Bars with different letters are significantly different at P≤0.05.   
 
Group D: Normoglycemic untreated rats. 
Group E: Normoglycemic treated with C. verum. 
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CHAPTER FOUR 
DISCUSSION 
 The current study was carried out to investigate the putative 
hypoglycemic and antidiabetic effect of Cinnamomum verum, one of 
Sudanese flavouring agents. C. verum is one of the tropical plants related 
to family Lauraceae. The medicinal using of Cinnamon as antidiabetic 
agent, was investigated by Khan et al. (2003), a pilot clinical trial was 
conducted in Pakistan to study the effect of Cinnamon cassia powder in 
patients with type 2 diabetes, average age was 52.2 ± 6.32. The study 
showed, successful result, that Cinnamomum cassia reduced fasting 
serumglucose (18 – 29%). Cinnamomum cassia a species closely related 
to Cinnamomum verum ("Cassia." Wikipedia, 2007). In this study, C. 
verum was examined for the hypoglycemic effect in induced 
hyperglycemic rats and normoglycemic fasting rats.  
Experiment 1 was conducted to study the effect of C. verum bark 
powder and Gibenclamide in glucose loaded rats. The study showed that 
C. verum powder reduced significantly serum glucose level at 2h and  
non-significantly at 4h when compared to the control but the reduction in   
serum glucose was less when compared to the antidiabetic drug 
Glibenclamide which caused significant reduction at 1, 2 and 4 hours 
when compared to control. These results are similar those Khan et al. 
(2007); however the C. verum in this experiment was administrated to the 
rats only at 0 h after fasting and not before. The results of this experiment 
are also in line with Mang et al. (2007) who reported moderate glucose 
lowering effect of aqueous cinnamon extract on fasting plasma glucose 
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(10.3% Vs 3.37%) when compared to the control group of type 2 
diabetes. However, the hypoglycemic effect observed in the present study 
and previous ones (Khan et al., 2003; Mang et al., 2007) was not noticed 
by Vanschoonbeek et al. (2006) who found no significant difference in 
the levels of fasting plasma glucose, and insulin at two weeks and six 
weeks of treatment. The results of this study also showed that C. verum 
produced hypoglycemic effect but to lesser extend when compared to the 
commonly used antidiabetic drug Glibenclamide.  
 Experiment 2 was conducted to study the effect of oral 
administration of C. verum in normoglycemic fasting rats. The results of 
this experiment showed C. verum reduced significantly the serum 
glucose level at hour 4 following treatment and nonsignificantly at hour 1 
and 2 when compared to control group which their glucose level 
remained almost constant throughout the experimental period. This 
proved that, C. verum could induced reduction of serum glucose level 
even of fasting animal. Khan et al. (2003) investigation revealed that 
cinnamon reduced blood glucose of type 2 diabetic patients whom 
received cinnamon for sometime while in experiment 2 of this study      
C. verum first administration reduced the fasting serum glucose level. 
The experiment 1 of this of investigation showed that   C. verum also 
reduced the serum glucose level of glucose loaded rats. These 
experiments confirm cinnamonhas hypoglycemic effect. 
        Jarvill-Taylor et al. (2001) established that the active component in 
cinnamon responsible for its insulin-like activity is a water-soluble 
chemical compound called methylhydroxychalcone polymer (MHCP). 
They found that MHCP was highly effective, providing essentially the 
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same biological activity as insulin itself. It was effective not only in 
increasing the uptake of glucose by cells, but also of stimulating the 
synthesis of glycogen, a polymeric form of glucose that is stored 
primarily in the liver and muscle tissues for use at times of peak energy 
demand, such as exercise. MHCP turned out to be synergistic with 
insulin in these actions, providing a net effect greater than the sum of its 
parts. MHCP makes cells more responsive to insulin, i.e., it increases 
insulin sensitivity, the opposite of insulin resistance. The C. verum used 
in the present experiments was not an extract of C. verum bark but rather 
whole powdered bark which of course contains MHCP along with every 
other compound of the bark, water soluble or not, thus the observed 
hypoglycemic of C. verum in this study may be attributed to its MHCP 
content. Researchers in Japan found recently that when an aqueous 
extract of cinnamon (containing MHCP, of course) was given orally to 
laboratory rats, the insulin receptors on skeletal muscle cells became 
more responsive (Qin et al., 2003). Enhanced insulin sensitivity means 
more glucose going into the cells, so the blood glucose levels fall, and 
biochemical order is restored. By enhancing insulin signaling, cinnamon 
can prevent insulin resistance even in animals fed a high-fructose diet. 
Qin et al. (2004) showed that when rats fed a high-fructose diet were also 
given cinnamon extract, their ability to respond to and utilize glucose 
was improved so much that it was the same as that of rats on a normal 
(control) diet. 
 Both test tube and animal studies have shown that compounds in 
cinnamon not only stimulate insulin receptors, but also inhibit an enzyme 
that inactivates them, thus significantly increasing cells' ability to use 
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glucose (Anderson et al., 2003). Anderson et al. (2003) characterized the 
insulin-enhancing complexes in cinnamona collection of catechin/ 
epicatechin oligomers that increase the body's insulin-dependent abiltiy 
to use glucose roughly 20-fold. 
 Antioxidant are essential to human body to neutralize free-reactive 
oxygen radical, to maintain functional cellular membrane and structure. 
Furthermore free radicals associated with impaired glucose metabolism 
and antioxidants have been implicated in regression of diabetes mellitus. 
Cinnamon contains oligomeric proanthocyanidins (OPC) which has anti-
oxidantive effect (Gu et al., 2003). The observed hypoglycemic effect of 
C. verum in this study may also be attributed to its content of OPC. 
 When rats were given a daily dose of cinnamon (300 mg Kg Bwt) 
for a three week period, their skeletal muscle was able to absorb 17% 
more blood sugar per minute compared to that of control rats, which had 
not received cinnamon. Khan et al. (2003) concluded that, including 
cinnamon in the diet of people with type 2 diabetes will reduce risk 
factors associated with diabetes and cardiovascular diseases. However, 
some scientists had been concerned about potentially toxic effects of 
regularly consuming cinnamon. New research showed that the potentially 
toxic compounds in cinnamon bark are found primarily in the lipid 
soluble fractions and are present only at very low levels in water soluble 
cinnamon extracts, which are the ones with the insulin-enhancing 
compounds. Cinnamon does not contain a measurable amount of 
goitrogen, oxalate or purine and is not known to cause food allergies 
(WH Food, 2007). Hence it could be concluded cinnamon water extract 
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can be used as hypoglycemic agent unless otherwise, further study 
proved it is toxic. 
CONCLUSIONS AND RECOMMENDATIONS 
Conclusions: 
 From observations and results of this investigation, it can be 
concluded that: 
1. C. verum bark powder decrease significantly plasma glucose level 
in the induced hypergycemic rats. 
2. Therefore, C. verum could be considered a promising antidiabetic 
agent which can be used to reduce blood glucose in diabetic 
patients.  
3. The effect of C. verum in the dose 1g/ kg body weight was less, 
when was compared to the effect of 10 mg/kgBwt of 
Gibenclamide. 
4. The dose 1g/kgBwt of C. verum bark powder has hypoglycemic 
effect in normoglycemic fasting rats. 
Recommendation: 
Since Cinnamomum verum is promising antidiabetic agent it is 
recommended that: 
1. The active ingredient in C. verum should be identified and 
fractionated. 
2. Future research should be carried out to determine the mechanism 
of action of each fraction on blood glucose level. 
3. The proper dosage and potential interactions with other medicinal 
plants and synthetic drugs, has to be studied. 
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4. The safety of C. verum should be examined by administrating very 
high dose for long period of time. 
5. The effect of C. verum to type 1diabetes has to be examined. 
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